Neovasc Inc. Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ valve in development for the transcatheter treatment of mitral valve disease, and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as transcatheter heart valves.

Industries:
Medical | Pharmaceuticals

Latest

Jul 17, 2019, 15:04 ET Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

NASDAQ, TSX: NVCN VANCOUVER, July 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jul 16, 2019, 08:55 ET Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Pending U.S. Food and Drug Administration ("FDA") Humanitarian Use Device ("HUD") Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early 2020 A...


Jul 15, 2019, 16:11 ET Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

Company Joined by Other Industry Leaders as Part of ISO Cardiac Valves Working Group NASDAQ, TSX: NVCN VANCOUVER, July 15, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: ...


Jul 12, 2019, 08:55 ET Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

NASDAQ, TSX: NVCN VANCOUVER, July 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 28, 2019, 07:00 ET Neovasc Announces Effective Date of Share Consolidation

NASDAQ, TSX: NVCN VANCOUVER, June 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 27, 2019, 08:55 ET Neovasc Announces Presentations on Tiara™ for Treatment of Mitral Regurgitation and Reducer™ for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, June 27, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 25, 2019, 14:30 ET Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN VANCOUVER, June 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 17, 2019, 08:55 ET Tiara™ Featured in Presentation at 11th Annual TVT 2019

NASDAQ, TSX: NVCN VANCOUVER, June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 07, 2019, 13:30 ET Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

NASDAQ, TSX: NVCN VANCOUVER, June 7, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of...


Jun 04, 2019, 14:15 ET Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, June 4, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual...


May 28, 2019, 08:55 ET Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, May 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 23, 2019, 09:17 ET New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

NASDAQ, TSX: NVCN VANCOUVER, May 23, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 22, 2019, 17:30 ET Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

NASDAQ, TSX: NVCN VANCOUVER, May 22, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 16, 2019, 20:00 ET Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

NASDAQ, TSX: NVCN VANCOUVER, May 16, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN) announced today that it has closed its previously announced private placement (the...


May 14, 2019, 07:00 ET Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

Upon closing of this agreement, cash and cash equivalents is expected to support operations into Q1 2020 NASDAQ, TSX: NVCN VANCOUVER, May 14, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company")...


May 09, 2019, 16:00 ET Neovasc Announces First Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights Announced the 1,000th recipient of a Neovasc ReducerTM ("Reducer") implant Company sponsored Reducer Symposium attended by over 100 attendees at the 85th Annual...


May 06, 2019, 08:55 ET Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, May 6, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 03, 2019, 07:30 ET Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Conference Call Scheduled for 4:30 pm Eastern Time on May 9th NASDAQ, TSX: NVCN VANCOUVER, May 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the...


Apr 26, 2019, 07:30 ET Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

NASDAQ, TSX: NVCN VANCOUVER, April 26, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Apr 17, 2019, 15:42 ET Neovasc Announces Resolution of Last Remaining Active Litigation

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Apr 17, 2019, 07:50 ET Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Mar 21, 2019, 16:01 ET Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory...


Mar 21, 2019, 07:50 ET Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

NASDAQ, TSX: NVCN VANCOUVER, March 21, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Mar 19, 2019, 07:50 ET Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

NASDAQ, TSX: NVCN VANCOUVER, March 19, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Mar 15, 2019, 14:30 ET Neovasc Announces Closing of $5 Million Public Offering of Common Shares

NASDAQ, TSX: NVCN VANCOUVER, March 15, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced underwritten...